NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

RecruitingN/A

Sponsor: UMC Utrecht

Conditions: Prurigo Nodularis (PN)

Interventions: Dupilumab

Countries: Netherlands

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment

Exclusion Criteria:

* Unwilling to participate in the BioDay registry
* (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank

Locations (1)

Utrecht, Utrecht, Netherlands